Preclinical pharmacology and toxicology study of an AAV8-tATP7B vector for Wilson’s disease
Clinical and Molecular Hepatology · 01.07.2026 · 32 (3) · 1240-1260
DOI: 10.3350/cmh.2025.1300 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.07.2026. Verfasst von Zixuan Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Hepatolenticular Degeneration, Genetic Vectors, Dependovirus, Adenosine Triphosphatases. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, National Key Research and Development Program of China, Shanghai Jiao Tong University School of Medicine.
Abstract (Originalsprache)
Background/Aims: Wilson’s disease (WD) is an autosomal recessive disorder of copper metabolism caused by Atp7b mutations. In this study, a novel gene therapy for WD was developed, and its efficacy and safety were evaluated in relevant animal models.
Methods
Codon-optimized full-length or truncated ATP7B (tATP7B) genes were assembled with liver-specific mini promoters to construct an adeno-associated virus serotype 8 vector (AAV8). The expression and activity of these vectors were evaluated in HepG2 cells. AAV8-tATP7B viral particles were produced using a triple-plasmid cotransfection system under good manufacturing practice conditions. Long-term efficacy was evaluated in Atp7b-/- mice at three doses (5×10¹¹, 5×10¹², and 1×10¹³ vg/kg). Single-dose toxicity was assessed over 13 weeks in Sprague– Dawley rats and cynomolgus macaques.
Results
In HepG2 cells, the ability of the tATP7B to export copper was comparable to that of the full-length protein, but the expression efficiency was greater. Alkaline gel electrophoresis confirmed its better compatibility with AAV packaging limits while maintaining genomic integrity, supporting its selection for AAV8-tATP7B production. In a 24- week study in Atp7b-/- mice, AAV8-tATP7B restored copper homeostasis and liver function in a dose-dependent manner and significantly reversed existing liver injury. Toxicity studies in Sprague‒Dawley rats and cynomolgus monkeys revealed no systemic toxicity, whereas reversible liver changes were observed in cynomolgus monkeys at high doses; thus, 6×10¹³ vg/kg was established as the maximum tolerated dose.
Conclusions
These results establish the efficacy and safety profile of AAV8-tATP7B and provide the rationale for its clinical translation in patients with WD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Hangzhou CoJourney Biotechnology Co Ltd, Zhejiang, China.
- Department of Biochemistry and Molecular Biology, Shanghai Jiao Tong University School of Medicine, Shangha, China.
- Department of Histology and Embryology, School of Basic Medical Science, Dali University, Yunnan, China.
- Department of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. rty0303@163.com.
Förderung
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- National Key Research and Development Program of China
- Shanghai Jiao Tong University School of Medicine
Zitieren
APA
Wang, Z., Wang, M., Wu, M., Ye, L., Lou, T., Sun, X., Zhao, W., Liu, F., Ren, T., Li, W., & Fan, J. G. (2026). Preclinical pharmacology and toxicology study of an AAV8-tATP7B vector for Wilson’s disease. Clinical and Molecular Hepatology, 32(3), 1240-1260. https://doi.org/10.3350/cmh.2025.1300
Vancouver
Wang Z, Wang M, Wu M, Ye L, Lou T, Sun X, et al. Preclinical pharmacology and toxicology study of an AAV8-tATP7B vector for Wilson’s disease. Clinical and Molecular Hepatology. 2026;32(3):1240-1260. doi:10.3350/cmh.2025.1300
BibTeX
@article{Wang2026,
author = {Wang, Zixuan and Wang, Mengyu and Wu, Mengyuan and Ye, Lei and Lou, Tianwen and Sun, Xuxu and Zhao, Wenzheng and Liu, Fang and Ren, Tianyi and Li, Wuping and Fan, Jian-Gao},
title = {Preclinical pharmacology and toxicology study of an AAV8-tATP7B vector for Wilson’s disease},
journal = {Clinical and Molecular Hepatology},
year = {2026},
volume = {32},
number = {3},
pages = {1240--1260},
doi = {10.3350/cmh.2025.1300}
}
EUVIMED